This is a column about how dysfunction in Washington is handing billions over to Wall Street while threatening thousands of jobs on the Central Coast. Just a year ago, Allergan shut its Goleta breast implant operation after it came under siege from corporate raiders, Activis, a New Jersey-based company that used an acquisition in Ireland Read More →
One of the biggest employers in Ventura County faces an ownership change less than one month after it was spun off from its Chicago-area parent. Shire Plc, a pharma company based in Dublin, Ireland, stunned the markets on Aug. 4 with a $30 billion bid for Baxalta. Baxalta, which employs around 2,000 at two locations Read More →
Thousand Oaks-based Amgen Inc. posted second-quarter profit that topped analysts’ estimates, driven by higher sales and lower operating expenses. The biotech also raised its revenue and earnings forecast for the year. Profit excluding one-time items rose to $2.57 a share, while analysts had predicted $2.43 on average. Revenue increased 3.7 percent to $5.37 billion, the Read More →
Thousand Oaks-based Amgen announced Thursday that it submitted data comparing its new multiple-myeloma drug against a rival to the Food and Drug Administration. Kyprolis is Amgen’s new treatment for multiple-myeloma, which is a form of blood cancer that forms in plasma cells and typically grows in bone marrow. The drug was approved for third-line treatments Read More →
Teledyne Technologies won an out of this world contract Tuesday. Thousand Oaks-based Teledyne announced that it won a $15 million contract from NASA on Monday to build a hyper-spectral remote sensing imaging instrument that will be used on the International Space Station. Teledyne makes instrumentation, digital imaging products and software for aerospace and defense systems. Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
